{"id":"biod-123","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypoglycemia"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Lipodystrophy"}]},"_chembl":{"chemblId":"CHEMBL245839","moleculeType":"Small molecule","molecularWeight":"380.83"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"BIOD-123 combines insulin lispro with proprietary excipients to accelerate insulin absorption and onset of action compared to standard rapid-acting insulins. This allows for faster glucose lowering after meals and potentially improved overall glycemic control with more physiologic insulin kinetics.","oneSentence":"BIOD-123 is a rapid-acting insulin formulation designed to improve postprandial glucose control in diabetes patients.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T03:24:09.720Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 1 diabetes mellitus"},{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT01686620","phase":"PHASE2","title":"A Study Evaluating Safety and Efficacy of BIOD-123 Compared to Insulin Lispro (Humalog®)","status":"COMPLETED","sponsor":"Biodel","startDate":"2012-08","conditions":"Type 1 Diabetes Mellitus","enrollment":132},{"nctId":"NCT01908894","phase":"PHASE1","title":"Pharmacokinetic and Pharmacodynamic Properties of BIOD-123 and BIOD-125 Compared to Humalog® in Subjects With Type 1 Diabetes Including Assessments of Injection Site Toleration","status":"COMPLETED","sponsor":"Biodel","startDate":"2012-02","conditions":"Diabetes Mellitus","enrollment":12}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"BIOD-123","genericName":"BIOD-123","companyName":"Biodel","companyId":"biodel","modality":"Small molecule","firstApprovalDate":"","aiSummary":"BIOD-123 is a rapid-acting insulin formulation designed to improve postprandial glucose control in diabetes patients. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}